Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has undergone rapid changes with innovations in oncogene-directed therapy and immune checkpoint inhibitors. In patients with epidermal growth factor receptor (EGFR) gene mutant (EGFRm) NSCLC, newer-generation tyrosine...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiest, Nathaniel, Majeed, Umair, Seegobin, Karan, Zhao, Yujie, Lou, Yanyan, Manochakian, Rami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634952/
https://www.ncbi.nlm.nih.gov/pubmed/34868953
http://dx.doi.org/10.3389/fonc.2021.751209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634952/
https://www.ncbi.nlm.nih.gov/pubmed/34868953
http://dx.doi.org/10.3389/fonc.2021.751209

Ejemplares similares